Sangamo Therapeutics and Astellas Collaborate on Innovative Gene Therapy for Neurological Diseases

FDA Clears IND for Arbor Biotechnologies’ ABO-101 Gene Editing Therapeutic for Primary Hyperoxaluria Type 1

Fortis Healthcare Acquires Stake in Agilus Diagnostics

FDA Approves BRAFTOVI® Combination Regimen as First-Line Treatment for BRAF V600E-Mutant Metastatic Colorectal Cancer

The Role of Big Data in Precision Medicine

Caris Life Sciences Celebrates 1,000+ Precision Medicine Studies, Advancing Cancer Research and Patient Outcomes

OncoHelix and Qualisure Diagnostics Partner to Bring Thyroid GuidePx® Test to Canadian Patients

Gates Foundation Invests $50 Million in Tessera Therapeutics to Advance Gene Therapy for Sickle Cell Disease

FDA Approves Ensartinib (Ensacove) as First-Line Treatment for ALK-Positive NSCLC

Guardant Health and Boehringer Ingelheim Collaborate to Advance Liquid Biopsy CDx for HER2-Targeted Therapy in NSCLC

Cartherics Receives $300K G-Rex Grant to Advance Cancer Cell Therapy Manufacturing

Roche Revolutionizes Mass Spectrometry Diagnostics with Launch of cobas® Mass Spec Solution

Complete Genomics Partners with Eurofins Clinical Enterprise to Expand Sequencing Service Offerings

NeuroKaire Secures $10M to Transform Precision Medicine in Psychiatry and Neurology

Redcliffe Labs Announces Leadership Transition to Drive Healthcare Accessibility

Home
/
update
/
details

Myriad Genetics Partners with GSK to Enhance HRD Testing Accessibility Across Nine Nations

NextEdge Admin

12 Jun 2024

2 min 15 sec

Myriad Genetics, has entered into a collaboration with GSK to broaden access to homologous recombination deficiency (HRD) diagnostic testing for high-grade serous ovarian cancer (HGSOC) patients. Through this partnership, a sponsored testing program employing Myriad’s MyChoice HRD Plus and MyChoice CDx Plus Tests is being introduced across several countries, including Argentina, Brazil, and the United Arab Emirates. These tests serve a critical role in identifying HRD status, equipping clinicians with valuable information to make personalized treatment decisions for individuals battling ovarian cancer.

The collaboration between Myriad Genetics and GSK aims to address the pressing need for accessible testing solutions in underserved markets, ensuring that patients, regardless of their geographic location, can benefit from advanced genetic insights. Patrick Burke, the Executive Vice President of Strategy and Innovation at Myriad Genetics, highlighted the significance of this collaboration in advancing healthcare equity and extending the reach of diagnostic solutions to support tailored patient care based on individual genomic profiles.

Myriad’s MyChoice Test stands out as the most comprehensive tumor test available, offering a detailed analysis of genomic alterations, including in genes such as BRCA1 and BRCA2, alongside the Genomic Instability Score (GIS) status determined through a proprietary algorithm. This depth of analysis enables healthcare professionals to identify patients who are more likely to respond to treatment with targeted therapies, thereby improving treatment outcomes and patient quality of life.